News

November 12, 2019
IGM Biosciences to Present at Three Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced that Fred Schwarzer , Chief Executive Officer,
Additional Formats
November 7, 2019
IGM Biosciences Announces Third Quarter 2019 Financial Results
MOUNTAIN VIEW, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, today announced its financial results for the third quarter ended
Additional Formats
September 17, 2019
IGM Biosciences Announces Pricing of Initial Public Offering
MOUNTAIN VIEW, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the pricing of its initial public offering of 10,937,500 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading on The Nasdaq
Additional Formats
January 3, 2019
IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer
Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience  IGM Biosciences, Inc.  (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Misbah Tahir to the newly
Additional Formats